Cure8 research brief
If confirmed, the results suggest early-life exposures that perturb the gut microbiome may influence later risk of spondyloarthritis, which could be relevant for parents and clinicians weighing risks and benefits of infant antibiotic use and for researchers studying disease prevention.
Researchers studying IBD and spondyloarthritis, pediatricians and clinicians who prescribe infant antibiotics, parents/caregivers of young children, and patients with or at risk for psoriatic arthritis or other SpA.
The study compared 560 physician-recorded SpA cases to matched controls and used prescription and medical-record data to define exposures. Primary exposure was systemic antibiotics in the first year of life; investigators also looked at antibiotic class and early upper respiratory infections.
The reported associations were statistically adjusted and a dose-response test was performed. The finding was strongest for psoriatic arthritis in subgroup analysis and for broad-spectrum penicillins. Early upper respiratory tract infection was also independently associated with SpA; delivery mode and nonbacterial systemic antimicrobials were not associated.
This is an observational, register-based study: it identifies associations but cannot prove antibiotics cause SpA. It does, however, add to literature suggesting early-life microbiome influences immune-mediated disease risk.
This is an abstract-based summary of a population-based observational study from Danish registries. Observational associations can be affected by confounding (indication for antibiotics, healthcare-seeking behavior) and do not establish causation. The article reports subgroup and class-specific findings that warrant replication before changing clinical practice.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Antibiotics commonly used against anaerobes affected opportunistic IBD-associated strains and beneficial commensals differently in lab cultures; this could influence thinking about using broad‑spectrum antibiotics to...
Adherent-invasive E. coli (AIEC) is implicated in Crohn’s disease inflammation in some patients. This review maps possible ways to target AIEC specifically, which could lead to therapies that reduce infection-driven...
Anti-drug antibodies can make anti-TNF biologics stop working for people with Crohn’s disease. This trial tests a simple, short antibiotic course given before starting anti-TNF therapy to see if it lowers antibody...
